Skip to main content
. 2021 Mar 9;11:619013. doi: 10.3389/fonc.2021.619013

Figure 4.

Figure 4

Silencing RhoV inhibited EGFR signaling pathway activation and promoted gefitinib sensitivity in PC9 and PC9-GR cells. (A) Western blot analysis of RhoV expression in PC9 and PC9-GR cell lines. (B) Western blot analysis of the mechanism of the EGFR signaling pathway after knockdown RhoV. (C) IHC analysis of p-AKT and p-ERK expressions in shScramble and shRhoV tumors. (D) CCK8 analysis of determining IC50 value against gefitinib of PC9 and PC9-GR cell with or without transfected esiRhoV. (Compared with match control, *p < 0.05, **p < 0.01.) (E) Flow cytometer analysis of gefitinib-induced PC9 and PC9-GR cells apoptosis percentage before or after transfected esiRhoV. (Compared with match control, *p < 0.05, **p < 0.01).